Endpoint Clinical is a clinical trial technology company specializing in Randomization and Trial Supply Management (RTSM). Its platforms, including PULSE and the newer Elosity platform, help pharmaceutical and biotechnology sponsors and CROs manage patient randomization, investigational product supply, study changes, integrations and trial operations. Endpoint has supported more than 2,300 studies across 90+ countries and more than one million patients. Its Elosity platform includes embedded eloAI capabilities for natural-language access to RTSM data, operational insights and automation. In 2026, Endpoint acquired Bluefin to expand into clinical supply forecasting and planning.
Endpoint Clinical offers candidates the opportunity to build technology used in global clinical trials, where software reliability, data integrity and regulatory compliance directly affect study operations and patients. The company has supported more than 2,300 studies across 90+ countries and continues to invest in next-generation RTSM, AI and clinical supply technology through products such as Elosity, eloAI and Bluefin. Current engineering roles include React, TypeScript, Go, C#, AWS, Azure, GitHub Actions and infrastructure-as-code technologies. Endpoint also has engineering and testing teams in Bengaluru and Hyderabad and was recognized by Built In as a Top 100 Midsize Place to Work from 2021 through 2025.
Frontend
Frontend
Backend
Backend
Backend
Backend
Web Development
Cloud Infrastructure
Cloud Infrastructure
CI/CD
Infrastructure as Code
Infrastructure as Code
Founder of Endpoint Clinical, established in 2009 to develop technology for clinical trial randomization and trial supply management. Public company databases identify Dole as the founder of the business, which grew into a global RTSM provider serving pharmaceutical, biotechnology and CRO customers.
CEO of Endpoint Clinical since 2025 with more than 30 years of experience across healthcare, life sciences, digital, data and AI. He previously served as Chief Digital Officer for R&D Solutions at IQVIA, Chief Growth Officer at EXL and Venture Partner at Cognizant. At Endpoint he leads technology strategy, market expansion and growth.
Chief Operating Officer at Endpoint Clinical and a member of its executive leadership team. She oversees operational execution across the organization and plays a key role in delivering Endpoint's RTSM technology and services to global clinical trial customers.
Chief Commercial Officer at Endpoint Clinical with more than three decades of life sciences and technology leadership experience. He previously served as COO at Real Chemistry, led life sciences and provider businesses at Emids and held senior life sciences leadership roles at Cognizant. He leads Endpoint's commercial growth and customer strategy.
Endpoint Clinical
Endpoint Clinical acquired Bluefin, a clinical supply forecasting and planning technology provider. The acquisition expands Endpoint beyond RTSM execution into supply planning while keeping Bluefin independently available to customers using other RTSM platforms.
Read articleEndpoint Clinical
Endpoint released Elosity R3 with expanded clinical supply management, study execution, governance and AI capabilities. The release includes eloAI-powered natural-language interaction with RTSM data, operational analytics, patient rollover, central pharmacy management and expanded supply optimization.
Read articleEndpoint Clinical
Endpoint Clinical was recognized as a Leader in Everest Group's 2025 Life Sciences RTSM Products PEAK Matrix assessment, which evaluates vendors on market impact, technology capabilities, strategy, flexibility and customer support.
Read articleNo open roles available
Check back later for new opportunities.
